Frailty and genetic risk predict fracture after lung transplantation

Macrae, Trisha A.; Lazo, Jose; Viduya, Judy; Florez, Rebecca; Dewey, Katherine; Gao, Ying; Singer, Jonathan P.; Hays, Steven R.; Golden, Jeffrey A.; Kukreja, Jasleen; Greenland, John R.; Calabrese, Daniel R.

doi:10.1016/j.ajt.2022.11.017

Cited by 4 publications

(1 citation statement)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The concept of frailty is recognized as an important factor that particularly impacts wait‐list survival, perioperative morbidity and also potentially mortality 13 . While a successful LTx can reverse the frailty phenotype in the short term, recent studies have linked frailty to long term morbidity in the form of fracture risk 14 and CLAD 15 . Given the importance of characterizing frailty‐related LTx outcomes, 16 a consensus Lung Transplant Frailty Scale has just been developed for future detailed frailty evaluation 17 …”

Section: Lung Transplant Recipient Selectionmentioning

confidence: 99%

Advances in lung transplantation: 60 years on

Paraskeva,

Snell

2024

Respirology

View full text Add to dashboard Cite

Lung transplantation is a well‐established treatment for advanced lung disease, improving survival and quality of life. Over the last 60 years all aspects of lung transplantation have evolved significantly and exponential growth in transplant volume. This has been particularly evident over the last decade with a substantial increase in lung transplant numbers as a result of innovations in donor utilization procurement, including the use donation after circulatory death and ex‐vivo lung perfusion organs. Donor lungs have proved to be surprisingly robust, and therefore the donor pool is actually larger than previously thought. Parallel to this, lung transplant outcomes have continued to improve with improved acute management as well as microbiological and immunological insights and innovations. The management of lung transplant recipients continues to be complex and heavily dependent on a tertiary care multidisciplinary paradigm. Whilst long term outcomes continue to be limited by chronic lung allograft dysfunction improvements in diagnostics, mechanistic understanding and evolutions in treatment paradigms have all contributed to a median survival that in some centres approaches 10 years. As ongoing studies build on developing novel approaches to diagnosis and treatment of transplant complications and improvements in donor utilization more individuals will have the opportunity to benefit from lung transplantation. As has always been the case, early referral for transplant consideration is important to achieve best results.

show abstract